Regenerative Therapy

Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells
Yong Zhao, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, Ye Zhang, Yalin Diao, Yunxiang Li, Yingjian Chen, Xiaoming Sun, Mary Beth Fisk, Randal Skidgel, Mark Holterman, Bellur Prabhakar and Theodore Mazzon
BMC Medicine 2012, 10:3  http://www.biomedcentral.com/1741-7015/10/3/abstract
“A procedure for Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop system that separate lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them …

Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.
Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, Kawa K, Koike K, Tauchi H, Kajiwara M, Hara T, Kato S; Japanese Cord Blood Bank Network.
Department of Paediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan.
“Umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between …

Retinal Degenerative Diseases – Review
 The retina is converting light signals into neural signals, which are then transmitted to the brain.
The retina is located in the inner surface of the eye and is part of the central nervous system (CNS).
Any defects involved in photoreceptors and transmission in the retina will lead to visual impairment. Currently, retinal degenerative diseases which involve neuron-cells death are the major causes of blindness in the western world.
 
Age-related macular degeneration (AMD)
Among the …

“Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis.”
Clin Pharmacol Ther. 2010 Jun;87(6):679-85
Rice CM et al.
SourceInstitute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol, UK.
“In this phase I study, we assessed the safety and feasibility of intravenous, autologous bone marrow (BM) cell therapy, without immunosuppressive preconditioning, in six patients with clinically definite, relapsing-progressive multiple sclerosis (MS)”
“The lack of serious adverse effects and the suggestion of a beneficial effect in this …

Two clinical studies testing autologous cord blood infusion for treatment of children with cerebral palsy, now recruiting patients (November 2011):
1. “Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children”
http://www.clinicaltrials.gov/ct2/show/NCT01072370?term=cerebral+palsy&rank=1

Medical College of Georgia
 

Augusta, Georgia, United States

2. “A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy”
http://www.clinicaltrials.gov/ct2/show/NCT01147653?term=cerebral+palsy&rank=5

Duke University Medical Center
 

Durham, North Carolina, United States

The randomized, placebo-controlled Phase 2 trial compared the safety and efficacy of three doses of Revascor™ on top of maximal approved therapies versus maximal therapies alone in the patients, all with moderate-to-severe congestive heart failure.
Mesoblast Limited  announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor™ (mesenchymal stem cells) after all patients had completed a minimum follow-up of 12 months.
Treatment pooled across all doses in 45 patients …

November 14 2011 Geron said it would stop enrolling patients in its study of a stem cell-based treatment for spinal cord injury, after treating four patients.
Sep tember 2010 Phase I trial to evaluate GRNOPC1 in patients with  grade A subacute thoracic spinal cord injuries. The primary study endpoint is safety, but additional secondary endpoints will assess efficacy of the treatment in terms of improved neuromuscular control or sensation in the trunk or lower extremities.
GRNOPC1 is Geron’s cell product …

Pilot clinical trial to “Evaluate Safety and Efficacy of Autologous Bone Marrow-derived Endothelial Progenitor Cells in Advanced Liver Cirrhosis”
 Study to evaluate the safety and therapeutic effects of autologous bone marrow-derived endothelial progenitor cells (EPCs),  administered through the hepatic artery of patients with advanced liver cirrhosis.
Clinical trial website:
http://clinicaltrials.gov/ct2/show/NCT01333228?term=Navarra+cirrhosis&rank=1
Sponsored: Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra, Spain. 
October 2011 recruiting patients

Phase II study to examine survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
Bladder cancer
Renal pelvis cancer
Ureteral cancer
Urethral cancer
Vaccine consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated in vitro with a recombinant fusion protein.
Multi center study in several sites in the US. October 2011 recruiting patients.
Clinical trials website:
http://clinicaltrials.gov/ct2/show/NCT01353222?term=dendreon&rank=3
Company website:
http://www.dendreon.com/

Pilot Study Evaluating the Safety and Efficacy of Transplantation of UCB-derived ex Vivo Expanded Stem and Progenitor Cells (NiCord), in Combination With a Second, Unmanipulated CBU in Patients With Hematological Malignancies (ALL, AML, Myelodysplastic Syndrome (MDS), Non-Hodgkin’s lymphoma or Hodgkin’s disease).
Study coducted at: United States, North Carolina Duke University Medical Center
 Presently recruiting patients 10.2011
Clinica Trials website: 
http://clinicaltrials.gov/ct2/show/NCT01221857?term=gamida+cell&rank=1
Gamida Cell Ltd. Israel:
http://www.gamida-cell.com/products.asp?ID=4&t=NiCord™